Esperion Therapeutics, Inc. (LON:0IIM)
London
· Delayed Price · Currency is GBP · Price in USD 0.7862
-0.1139 (-12.65%)
At close: May 9, 2025
Esperion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 259.57 | 332.31 | 116.33 | 75.48 | 78.45 | 227.55 | Upgrade
|
| Revenue Growth (YoY) | 12.99% | 185.66% | 54.14% | -3.79% | -65.53% | 53.37% | Upgrade
|
| Cost of Revenue | 135.46 | 114.84 | 129.37 | 145.89 | 120.19 | 149.33 | Upgrade
|
| Gross Profit | 124.12 | 217.48 | -13.04 | -70.42 | -41.75 | 78.22 | Upgrade
|
| Selling, General & Admin | 164.08 | 163.07 | 142.52 | 109.08 | 171.74 | 199.62 | Upgrade
|
| Operating Expenses | 164.08 | 163.07 | 142.52 | 109.08 | 171.74 | 199.62 | Upgrade
|
| Operating Income | -39.96 | 54.4 | -155.56 | -179.5 | -213.48 | -121.4 | Upgrade
|
| Interest Expense | -64.66 | -59.25 | -58.98 | -56.81 | -46.35 | -22.67 | Upgrade
|
| Interest & Investment Income | 6.3 | 7.6 | 4.4 | 2.4 | 0.1 | 0.5 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.02 | 0.42 | 0.48 | 0.53 | 1.24 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | -98.3 | 3.17 | -209.66 | -233.38 | -258.49 | -143.65 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | 0.41 | -0.28 | -0.01 | 0.1 | Upgrade
|
| Legal Settlements | - | - | - | - | -18.25 | - | Upgrade
|
| Other Unusual Items | -54.92 | -54.92 | - | - | 2.65 | - | Upgrade
|
| Pretax Income | -153.22 | -51.75 | -209.25 | -233.66 | -269.11 | -143.55 | Upgrade
|
| Net Income | -153.22 | -51.75 | -209.25 | -233.66 | -269.11 | -143.55 | Upgrade
|
| Net Income to Common | -153.22 | -51.75 | -209.25 | -233.66 | -269.11 | -143.55 | Upgrade
|
| Shares Outstanding (Basic) | 194 | 187 | 103 | 66 | 29 | 27 | Upgrade
|
| Shares Outstanding (Diluted) | 194 | 187 | 103 | 66 | 29 | 27 | Upgrade
|
| Shares Change (YoY) | 54.12% | 81.54% | 55.26% | 129.76% | 5.20% | 1.42% | Upgrade
|
| EPS (Basic) | -0.79 | -0.28 | -2.03 | -3.52 | -9.31 | -5.22 | Upgrade
|
| EPS (Diluted) | -0.81 | -0.28 | -2.03 | -3.52 | -9.31 | -5.22 | Upgrade
|
| Free Cash Flow | -100.35 | -23.97 | -135.49 | -174.83 | -263.81 | -86.05 | Upgrade
|
| Free Cash Flow Per Share | -0.52 | -0.13 | -1.31 | -2.63 | -9.13 | -3.13 | Upgrade
|
| Gross Margin | 47.82% | 65.44% | -11.21% | -93.30% | -53.21% | 34.38% | Upgrade
|
| Operating Margin | -15.40% | 16.37% | -133.72% | -237.83% | -272.13% | -53.35% | Upgrade
|
| Profit Margin | -59.03% | -15.57% | -179.87% | -309.58% | -343.04% | -63.09% | Upgrade
|
| Free Cash Flow Margin | -38.66% | -7.21% | -116.46% | -231.64% | -336.29% | -37.81% | Upgrade
|
| EBITDA | -39.92 | 54.47 | -155.4 | -179 | -212.87 | -120.85 | Upgrade
|
| EBITDA Margin | -15.38% | 16.39% | -133.58% | -237.17% | -271.35% | -53.11% | Upgrade
|
| D&A For EBITDA | 0.05 | 0.06 | 0.16 | 0.5 | 0.61 | 0.55 | Upgrade
|
| EBIT | -39.96 | 54.4 | -155.56 | -179.5 | -213.48 | -121.4 | Upgrade
|
| EBIT Margin | -15.40% | 16.37% | -133.72% | -237.83% | -272.13% | -53.35% | Upgrade
|
| Revenue as Reported | 259.57 | 332.31 | 116.33 | 75.48 | 78.45 | 227.55 | Upgrade
|
| Advertising Expenses | - | 25.5 | 15.6 | 11.3 | 13.7 | 19.3 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.